Parexel moves to pick up laid-off GlaxoSmithKline workers

Parexel ($PRXL) is leasing a North Carolina building from GlaxoSmithKline ($GSK), part of a deal between the two in which the CRO will absorb some researchers on the way out as the drugmaker mounts a major restructuring. As the Triangle Business Journal reports, the plan is for Parexel to take up an outpost on GSK's local campus and hire up as many as 500 of the roughly 1,000 workers the U.K. giant is cutting in the area. The swap is slated to wrap up in March. More

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.